Article

HTA Quarterly Summer 2025

In this edition, our experts explore the health technology assessment (HTA) process and policies in Japan, describe early access program (EAP) pathways in France (in the first of a three-part series of articles on this topic), and consider potential impacts of the Joint Clinical Assessment (JCA) and Project Orbis on revenue generation for new medicinal products in oncology.
HTAQ Summer 2025

Article

Early Access Program in France: How much of an opportunity is it?

HTAQ Summer 2025

Article

HTA in Japan: The glass remains half full (for now)

HTAQ Summer 2025

Article

New opportunities for medicines in Europe? How JCA and Project Orbis may impact the revenue potential of innovative medicines

Heard on the street

“If the JCA could help build a European market, accelerating the process and allowing developers to save one or two years after marketing approval, that is what would attract investment in clinical trials in Europe.”

- Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon, on the potential of the JCA to promote a competitive life sciences sector in Europe.

Source: Event Report--The First Joint Clinical Assessments for ATMPs: What's Next?

HTA by the numbers

2 of 25
The European Commission recently announced that the first two Joint Clinical Assessments (JCAs) are underway, evaluating a medicinal product for the treatment of pediatric low-grade glioma (led by health technology assessment [HTA] agencies from Ireland and Germany) and an advanced therapy medicinal product (ATMP) for the treatment of melanoma (led by HTA agencies from France and Poland). The Member State Coordination Group on HTA (HTACG) has previously estimated that 25 JCAs will be started in 2025.

Source: Health Technology Assessment: First Joint Clinical Assessments Begin


Connect with our team

Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.

Related resources

Article

Five frequent inspection findings and the role of the QPPV
Learn more

Article

Harmonizing Health Technology Assessment: PICO consolidation under the EU HTA Regulation
Learn more

Article

Breaking down medication access barriers through innovative pharmacy solutions
Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.